Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.
McKenzie DR, Graham R, Lechmere T, Domingo-Vila C, Alaguthurai T, Arman C, Pollock E, Gousis C, Kakkassery H, Carpenter E, Kurshan A, Vidler J, Kulasekararaj A, Patten P, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: lechmere t. Cancer Res Commun. 2022 Nov 17;2(11):1449-1461. doi: 10.1158/2767-9764.CRC-22-0298. Cancer Res Commun. 2022. PMID: 36824220 Free PMC article.
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
Graham C, Lechmere T, Rehman A, Seow J, Kurshan A, Huettner I, Maguire TJA, Tam JCH, Cox D, Ward C, Racz M, Waters A, Mant C, Malim MH, Fox J, Doores KJ. Graham C, et al. Among authors: lechmere t. PLoS Pathog. 2022 Oct 3;18(10):e1010882. doi: 10.1371/journal.ppat.1010882. eCollection 2022 Oct. PLoS Pathog. 2022. PMID: 36191037 Free PMC article.
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.
Harrington P, Kurshan A, Delord M, Lechmere T, Sheikh A, Saunders J, Saha C, Dillon R, Woodley C, Asirvatham S, Curto-Garcia N, Sullivan JO, Kordasti S, Radia D, McLornan D, Malim MH, Harrison C, Doores KJ, de Lavallade H. Harrington P, et al. Among authors: lechmere t. Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375. Blood Adv. 2023. PMID: 36083126 Free PMC article. No abstract available.
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Seow J, Graham C, Hallett SR, Lechmere T, Maguire TJA, Huettner I, Cox D, Khan H, Pickering S, Roberts R, Waters A, Ward CC, Mant C, Pitcher MJ, Spencer J, Fox J, Malim MH, Doores KJ. Seow J, et al. Among authors: lechmere t. Cell Rep. 2022 May 3;39(5):110757. doi: 10.1016/j.celrep.2022.110757. Epub 2022 Apr 15. Cell Rep. 2022. PMID: 35477023 Free PMC article.
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Harrington P, Doores KJ, Saunders J, de Lord M, Saha C, Lechmere T, Khan H, Lam HPJ, Reilly AO, Woodley C, Asirvatham S, Dillon R, Curto-Garcia N, Sullivan JO, Kordasti S, Raj K, Malim MH, Radia D, McLornan D, Harrison C, de Lavallade H. Harrington P, et al. Among authors: lechmere t. Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3. Blood Cancer J. 2022. PMID: 35459222 Free PMC article. No abstract available.
BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes.
Abdul-Jawad S, Beatson R, Lechmere T, Graham R, Alaguthurai T, Graham C, Vidler J, Kulasekararaj A, Patten PEM, Doores KJ, Irshad S. Abdul-Jawad S, et al. Among authors: lechmere t. Haematologica. 2022 May 1;107(5):1181-1184. doi: 10.3324/haematol.2021.280337. Haematologica. 2022. PMID: 35045695 Free PMC article. No abstract available.
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Harrington P, Doores KJ, Saha C, Saunders J, Child F, Dillon R, Saglam S, Raj K, McLornan D, Avenoso D, Kordasti S, O'Reilly A, Espehana A, Lechmere T, Khan H, Malim MH, Harrison C, Mehra V, de Lavallade H. Harrington P, et al. Among authors: lechmere t. Cancer Cell. 2021 Dec 13;39(12):1654. doi: 10.1016/j.ccell.2021.11.011. Cancer Cell. 2021. PMID: 34906318 Free PMC article. No abstract available.
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Khan H, Lechmere T, Malim MH, Meynell F, Pollock E, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree T, Smith CH. Mahil SK, et al. Among authors: lechmere t. Lancet Rheumatol. 2022 Jan;4(1):e42-e52. doi: 10.1016/S2665-9913(21)00333-7. Epub 2021 Nov 9. Lancet Rheumatol. 2022. PMID: 34778846 Free PMC article.
17 results